Ann Knight

1.7k total citations
30 papers, 937 citations indexed

About

Ann Knight is a scholar working on Pulmonary and Respiratory Medicine, Rheumatology and Surgery. According to data from OpenAlex, Ann Knight has authored 30 papers receiving a total of 937 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pulmonary and Respiratory Medicine, 12 papers in Rheumatology and 5 papers in Surgery. Recurrent topics in Ann Knight's work include Vasculitis and related conditions (17 papers), Rheumatoid Arthritis Research and Therapies (8 papers) and Sarcoidosis and Beryllium Toxicity Research (5 papers). Ann Knight is often cited by papers focused on Vasculitis and related conditions (17 papers), Rheumatoid Arthritis Research and Therapies (8 papers) and Sarcoidosis and Beryllium Toxicity Research (5 papers). Ann Knight collaborates with scholars based in Sweden, United States and Finland. Ann Knight's co-authors include Johan Askling, Anders Ekbom, Sven Sandin, Pär Sparén, Fredrik Granath, Dan Nordström, Tom Pettersson, Lena Brandt, Anders Ekbom and Ronald van Vollenhoven and has published in prestigious journals such as SHILAP Revista de lepidopterología, International Journal of Cancer and Frontiers in Immunology.

In The Last Decade

Ann Knight

29 papers receiving 911 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ann Knight Sweden 17 418 337 207 183 171 30 937
A. Masseau France 20 389 0.9× 562 1.7× 244 1.2× 249 1.4× 145 0.8× 84 1.2k
G. Le Guenno France 16 321 0.8× 322 1.0× 118 0.6× 286 1.6× 94 0.5× 49 946
J. Schmidt France 15 764 1.8× 476 1.4× 196 0.9× 150 0.8× 94 0.5× 58 1.1k
Curry L. Koening United States 22 889 2.1× 544 1.6× 249 1.2× 237 1.3× 166 1.0× 43 1.4k
Carla Maldini France 13 532 1.3× 525 1.6× 90 0.4× 151 0.8× 119 0.7× 20 1.0k
Karin Manger Germany 17 189 0.5× 746 2.2× 537 2.6× 88 0.5× 171 1.0× 30 1.3k
Claudia Sengler Germany 21 229 0.5× 300 0.9× 338 1.6× 331 1.8× 171 1.0× 46 1.2k
Robert A.F. de Lind van Wijngaarden Netherlands 7 972 2.3× 332 1.0× 198 1.0× 244 1.3× 147 0.9× 11 1.1k
Ko‐Ron Chen Japan 16 662 1.6× 583 1.7× 102 0.5× 123 0.7× 74 0.4× 39 1.1k
Meral Koniçe Türkiye 18 239 0.6× 496 1.5× 235 1.1× 56 0.3× 179 1.0× 38 934

Countries citing papers authored by Ann Knight

Since Specialization
Citations

This map shows the geographic impact of Ann Knight's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ann Knight with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ann Knight more than expected).

Fields of papers citing papers by Ann Knight

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ann Knight. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ann Knight. The network helps show where Ann Knight may publish in the future.

Co-authorship network of co-authors of Ann Knight

This figure shows the co-authorship network connecting the top 25 collaborators of Ann Knight. A scholar is included among the top collaborators of Ann Knight based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ann Knight. Ann Knight is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hoef, Vincent van, Ann Knight, Iva Gunnarsson, et al.. (2025). The plasma proteome reveals distinct signaling pathways associated with PR3-ANCA positive and MPO-ANCA positive vasculitis. Frontiers in Immunology. 16. 1600754–1600754.
2.
Lundtoft, Christian, Ann Knight, Jennifer R. S. Meadows, et al.. (2024). The HLA region in ANCA-associated vasculitis: characterisation of genetic associations in a Scandinavian patient population. RMD Open. 10(2). e004039–e004039. 2 indexed citations
3.
4.
Bower, Hannah, Thomas Frisell, Daniela Di Giuseppe, et al.. (2023). Are JAKis more effective among elderly patients with RA, smokers and those with higher cardiovascular risk? A comparative effectiveness study of b/tsDMARDs in Sweden. RMD Open. 9(4). e003648–e003648. 1 indexed citations
5.
6.
Sohrabian, Azita, Linda Mathsson‐Alm, Monika Hansson, et al.. (2018). Number of individual ACPA reactivities in synovial fluid immune complexes, but not serum anti-CCP2 levels, associate with inflammation and joint destruction in rheumatoid arthritis. Annals of the Rheumatic Diseases. 77(9). 1345–1353. 19 indexed citations
7.
Knight, Ann, Karlis Pauksens, Gunnel Nordmark, & Eva Kumlien. (2017). Fatal outcome of tick-borne encephalitis in two patients with rheumatic disease treated with rituximab. Lara D. Veeken. 56(5). kew495–kew495. 16 indexed citations
8.
Knight, Ann, et al.. (2016). Lifetime Physical Activity and Breast Cancer: a Case-Control Study in Kelantan, Malaysia.. PubMed. 17(8). 4083–8. 8 indexed citations
9.
Knight, Ann, Christer Sundström, Martin Höglund, et al.. (2015). Leukemia and Myelodysplastic Syndrome in Granulomatosis with Polyangiitis: Subtypes, Clinical Characteristics, and Outcome. The Journal of Rheumatology. 42(4). 690–694. 6 indexed citations
10.
11.
Chatzidionysiou, Katerina, Carl Turesson, Annika Teleman, et al.. (2012). A Multicenter, Randomized, Controlled, Open-Label Pilot Study of the Feasibility of Discontinuation of Adalimumab in Rheumatoid Arthritis Patients in Stable Clinical Remission. Arthritis & Rheumatism. 64. 12 indexed citations
12.
Nordström, Dan, Ann Knight, Reijo Luukkainen, et al.. (2012). Beneficial Effect of Interleukin 1 Inhibition with Anakinra in Adult-onset Still’s Disease. An Open, Randomized, Multicenter Study. The Journal of Rheumatology. 39(10). 2008–2011. 115 indexed citations
13.
Knight, Ann, et al.. (2012). AB0751 Successfull maintenance treatment of granulomatous polyangiitis (wegener) with rituximab - a case series. Annals of the Rheumatic Diseases. 71. 681–681. 1 indexed citations
14.
Knight, Ann, et al.. (2011). Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations. Rheumatology International. 32(2). 295–299. 96 indexed citations
15.
Knight, Ann, Sven Sandin, & Johan Askling. (2010). Increased Risk of Autoimmune Disease in Families with Wegener’s Granulomatosis. The Journal of Rheumatology. 37(12). 2553–2558. 21 indexed citations
16.
Knight, Ann, Sven Sandin, & Johan Askling. (2009). Occupational risk factors for Wegener's granulomatosis: a case–control study. Annals of the Rheumatic Diseases. 69(4). 737–740. 17 indexed citations
17.
Knight, Ann, Sven Sandin, & Johan Askling. (2007). Risks and relative risks of Wegener's granulomatosis among close relatives of patients with the disease. Arthritis & Rheumatism. 58(1). 302–307. 55 indexed citations
18.
Knight, Ann, Anders Ekbom, Lena Brandt, & Johan Askling. (2006). Increasing incidence of Wegener's granulomatosis in Sweden, 1975-2001.. PubMed. 33(10). 2060–3. 67 indexed citations
19.
Knight, Ann, Johan Askling, Fredrik Granath, Pär Sparén, & Anders Ekbom. (2004). Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide. Annals of the Rheumatic Diseases. 63(10). 1307–1311. 139 indexed citations
20.
Knight, Ann, Johan Askling, & Anders Ekbom. (2002). Cancer incidence in a population‐based cohort of patients with Wegener's granulomatosis. International Journal of Cancer. 100(1). 82–85. 150 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by A. Masseau Breakdown of academic impact, for papers by G. Le Guenno Breakdown of academic impact, for papers by J. Schmidt Breakdown of academic impact, for papers by Curry L. Koening Breakdown of academic impact, for papers by Carla Maldini Breakdown of academic impact, for papers by Karin Manger Breakdown of academic impact, for papers by Claudia Sengler Breakdown of academic impact, for papers by Robert A.F. de Lind van Wijngaarden Breakdown of academic impact, for papers by Ko‐Ron Chen Breakdown of academic impact, for papers by Meral Koniçe
Rankless by CCL
2026